Literature DB >> 15225867

Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid.

Matteo Bassetti1, Antonio Di Biagio, Valerio Del Bono, Giovanni Cenderello, Dante Bassetti.   

Abstract

We report the successful treatment with linezolid of a methicillin-resistant Staphylococcus aureus (MRSA) endocarditis in a patient with a severe allergic reaction to glycopeptides. Linezolid is a drug with well-recognised activity against S. aureus and proved to be efficacious even in the unusual site of heart valves. This drug could be a good therapeutic choice when glycopeptides treatment is not feasible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225867     DOI: 10.1016/j.ijantimicag.2003.12.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 2.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

3.  Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.

Authors:  Mustafa Sacar; Suzan Sacar; Nural Cevahir; Gokhan Onem; Zafer Teke; Ali Asan; Huseyin Turgut; Fahri Adali; Ilknur Kaleli; Ibrahim Susam; Yalin Tolga Yaylali; Ahmet Baltalarli
Journal:  Tex Heart Inst J       Date:  2010

4.  Linezolid for infective endocarditis: A structured approach based on a national database experience.

Authors:  P Muñoz; S De la Villa; M Martínez-Sellés; M A Goenaga; K Reviejo-Jaka; F Arnáiz de Las Revillas; L García-Cuello; C Hidalgo-Tenorio; M A Rodríguez-Esteban; I Antorrena; L Castelo-Corral; E García-Vázquez; J De la Torre; E Bouza
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.